Phase I Cetuximab and Concurrent Radio-chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2011

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Cetuximab

"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.~14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.~Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.~Vinorelbine:~Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."

Trial Locations (1)

Unknown

Maastricht Radiation Oncology, MAASTRO clinic, Maastricht

All Listed Sponsors
collaborator

Academisch Ziekenhuis Maastricht

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Maastricht Radiation Oncology

OTHER

NCT00522886 - Phase I Cetuximab and Concurrent Radio-chemotherapy | Biotech Hunter | Biotech Hunter